School of Health and Related Research, University of Sheffield, Sheffield, UK.
The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, School of Clinical Medicine, Cambridge, UK.
Cancer Rep (Hoboken). 2021 Aug;4(4):e1344. doi: 10.1002/cnr2.1344. Epub 2021 Feb 2.
Men have a greater risk of colorectal cancer (CRC) than women, but population screening currently starts at the same age for both sexes.
This analysis investigates whether, in a resource-constrained setting, it would be more effective and cost-effective for men and women to start screening for CRC at different ages.
An economic modeling analysis was carried out using the Microsimulation Model in Cancer of the Bowel to compare sex-stratification against screening everyone from the same age, taking an English National Health Service perspective. Screening men from age 56 and women from age 60, rather than screening everyone from age 58 using a Fecal Immunochemical Test (FIT) threshold of 120 μg/g is expected to produce an additional 0.0004 QALYs for a cost of £0.55 per person at model start (Incremental Cost-effectiveness Ratio = £1392), and to reduce CRC cases and mortality by 25 and 19 per 100 000 people respectively, while using a similar amount of screening resources. Probabilistic sensitivity analysis indicates a 61% probability that sex-stratification is more cost-effective than screening everyone at age 58. Similar benefits of sex-stratification are found at other FIT thresholds, but become negligible if mean screening start age is reduced to 50.
Where resources are constrained and it is not feasible to screen everyone from the age of 50, starting screening earlier in men than women is likely to be more cost-effective and gain more health benefits overall than strategies where men and women start screening at the same age.
男性患结直肠癌(CRC)的风险高于女性,但目前针对两性的人群筛查起始年龄相同。
本分析旨在探讨在资源有限的情况下,针对男性和女性设定不同的 CRC 筛查起始年龄是否会更有效且具有成本效益。
采用基于 Microsimulation Model in Cancer of the Bowel 的经济建模分析,从英国国家医疗服务体系的角度出发,比较了按性别分层筛查与对所有人群采用相同年龄筛查(即筛查起始年龄为 58 岁,粪便免疫化学检测 [FIT] 阈值为 120μg/g)的效果。相较于筛查起始年龄为 58 岁且 FIT 阈值为 120μg/g 的情况,筛查起始年龄为 56 岁的男性和 60 岁的女性(FIT 阈值仍为 120μg/g)预计将使模型启动时每个人的额外 QALYs 增加 0.0004,成本为每人 0.55 英镑(增量成本效益比为 1392 英镑),并分别使每 100000 人 CRC 病例和死亡率降低 25%和 19%,同时使用类似数量的筛查资源。概率敏感性分析表明,按性别分层筛查比筛查起始年龄为 58 岁的所有人群更具成本效益的可能性为 61%。在其他 FIT 阈值下,也能发现按性别分层筛查的类似获益,但如果将平均筛查起始年龄降低到 50 岁,这些获益就变得微不足道了。
在资源有限且无法对所有人进行 50 岁起始筛查的情况下,男性比女性更早开始筛查可能会更具成本效益,并且总体上会带来更多的健康获益,优于男性和女性筛查起始年龄相同的策略。